LAWRENCE BLATT - 08 Sep 2023 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Chief Executive Officer
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Lawrence M. Blatt
Issuer symbol
ALGS
Transactions as of
08 Sep 2023
Net transactions value
$0
Form type
4
Filing time
12 Sep 2023, 17:05:19 UTC
Previous filing
17 Mar 2023
Next filing
27 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 08 Sep 2023 Common Stock 150,000 $0.8400 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.